Benefits and challenges by microdosing substance

Benefits and challenges by microdosing substance

Subjective importance ratings were non-normally distributed thus Wilcoxon signed rank tests were used to compare between substances. There was a significant difference between shrooms dispensary near me the subjective rated importance of benefits based on substance (W = 3658, p < 0.01, N1 = 195, N2 = 50, d = 0.353) with psilocybin-only microdosers (median = 87.83, SD = 15.76) rating benefits as significantly more important than LSD-only microdosers (median = 76.67, SD = 14.59); there were no differences found relative to respondents using both LSD and psilocybin (median = 82.33, SD = 14.28, ps > 0.14). The substance-related difference between subjective importance of challenges was non-significant (W = 3841.5, p = 0.56, N1 = 177, N2 = 46, d = 0.079) with psilocybin-only microdosers (median = 47.67, SD = 24.98) rating challenges equivalently to LSD-only microdosers (median = 47.5, SD = 24.65); there were no differences found relative to respondents using both LSD and psilocybin (median = 51.67, SD = 23.79, ps > 0.66). Rates at which specific MDBC categories were reported did not differ between LSD-only, psilocybin-only, and LSD and psilocybin respondents (benefits χ2(20) = 17.26, p = 0.636; challenges χ2(20) = 7.73, p = 0.994).

Improvements and reductions

After reporting open-ended outcomes, participants answered targeted questions concerning behavioural improvements and substance-use reductions (Fig. 2). Respondents reported improved mood (92.9%), anxiety (59.2%), meditative practice (49.1%), exercise (49.1%), eating habits (36.0%), and sleep (28.8%). They also indicated reduced use of caffeine (44.2%), alcohol (42.3%), cannabis (30.3%), tobacco (21.0%), psychiatric prescription medications (16.9%), and illicit substances (16.1%).

Fig. 2

 

Percentage of microdosers endorsing improved behaviours and reductions in substance-use. Prevalence rate should be used for hypothesis generation as these data indicate reported outcomes, not confirmed effects. *Note: Anxiety refers to improvements to anxiety-related experiences, not to increased experience of anxiety

Discussion

Surveying extant communities of microdosers allowed for the creation of an initial qualitative taxonomy of MDBCs. These empirically-grounded MDBCs can inform future microdosing research by leveraging participant reports for high-potential intervention targets so research time and funding can be efficiently allocated. For example, microdosers often report changes in mood, focus, and creativity thus these constructs should be targeted in future intervention research. Concerns of physiological discomfort and restlessness were also commonly reported thus they should also be monitored.

While the improvements and reductions reported by respondents sound promising, they cannot be disentangled from expectation and placebo effects or recall biasses. Furthermore, the MDBC findings cannot indicate causation as this study was observational, not experimental. With these caveats in mind, we discuss how researchers can use these initial findings in their future studies. While necessarily inconclusive due to their exploratory nature, these results point to potential therapeutic effects warranting future placebo-controlled microdosing research.

 

Leave a Reply

Your email address will not be published. Required fields are marked *